Crossmark

Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents

Crossref DOI link: https://doi.org/10.1186/s12876-019-0973-5

Published Online: 2019-04-27

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hsu, Wei-Fan

Lai, Hsueh-Chou

Su, Wen-Pang

Lin, Chia-Hsin

Chuang, Po-Heng

Chen, Sheng-Hung

Chen, Hung-Yao

Wang, Hung-Wei

Huang, Guan-Tarn

Peng, Cheng-Yuan https://orcid.org/0000-0001-9030-6086
Funding

Funding for this research was provided by:

Ministry of Health and Welfare (MOHW106-TDU-B-212-113004)

China Medical University Hospital (No. DMR-107-211)
License Information

Text and Data Mining valid from 2019-04-27
More Information

Article History

Received: 18 September 2018

Accepted: 31 March 2019

First Online: 27 April 2019

Ethics approval and consent to participate

: The study was conducted in accordance with the 1975 Declaration of Helsinki. All patients provided written informed consent prior to enrollment, and this study was approved by the Research Ethics Committee of China Medical University Hospital, Taichung, Taiwan (CMUH106-REC2–105).

: Not applicable.

: Cheng-Yuan Peng has served as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead, and Merck Sharp & Dohme. All other coauthors have no conflicts of interest to declare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.